PROCEPT BioRobotics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
PROCEPT BioRobotics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities: | |||||||||||||||
| net income | -19,579,000 | -24,737,000 | -18,856,000 | -20,974,000 | -25,626,000 | -25,957,000 | -27,504,000 | -24,622,000 | -25,287,000 | -28,484,000 | -28,172,000 | -22,613,000 | -19,184,000 | -17,185,000 | -18,348,000 |
| adjustments to reconcile net income to cash from operating activities: | |||||||||||||||
| depreciation and amortization | 1,588,000 | 1,475,000 | 1,453,000 | 1,328,000 | 1,269,000 | 1,184,000 | 1,318,000 | 1,054,000 | 642,000 | 793,000 | 663,000 | 703,000 | 717,000 | 758,000 | 763,000 |
| stock-based compensation expense | 12,163,000 | 10,108,000 | 9,085,000 | 8,513,000 | 7,986,000 | 6,256,000 | 4,981,000 | 5,326,000 | 5,103,000 | 3,724,000 | 2,885,000 | 3,224,000 | 2,676,000 | 1,552,000 | 1,496,000 |
| change in fair value of derivative liability | 58,000 | 28,000 | 28,000 | 26,000 | |||||||||||
| non-cash lease adjustment | -127,000 | -127,000 | -96,000 | -96,000 | -95,000 | -96,000 | -110,000 | -192,000 | -180,000 | 495,000 | 833,000 | 838,000 | -96,000 | -97,000 | |
| inventory write-down | 160,000 | 330,000 | 600,000 | 376,000 | 0 | 581,000 | 186,000 | 228,000 | -25,000 | 113,000 | |||||
| benefit from credit losses | 600,000 | 300,000 | 384,000 | ||||||||||||
| (gain) loss on foreign currency transactions | |||||||||||||||
| changes in operating assets and liabilities: | |||||||||||||||
| accounts receivable | -2,706,000 | 3,929,000 | -14,832,000 | -10,587,000 | -2,835,000 | -7,706,000 | -13,754,000 | -1,448,000 | -12,531,000 | -5,370,000 | -2,434,000 | -1,945,000 | -3,901,000 | -2,529,000 | 1,890,000 |
| inventory | -4,786,000 | -6,282,000 | -5,797,000 | -7,158,000 | -2,794,000 | -1,486,000 | 3,186,000 | 485,000 | -3,286,000 | -10,136,000 | -5,749,000 | -8,818,000 | -1,201,000 | 517,000 | -2,544,000 |
| prepaid expenses and other current assets | 513,000 | 576,000 | -2,001,000 | -1,320,000 | 789,000 | -679,000 | -1,143,000 | -241,000 | 504,000 | 1,931,000 | -1,878,000 | -473,000 | 294,000 | 177,000 | -2,025,000 |
| other assets | -770,000 | -395,000 | -1,303,000 | -160,000 | 67,000 | -241,000 | -503,000 | -284,000 | 151,000 | 100,000 | |||||
| accounts payable | -2,250,000 | 3,754,000 | -5,379,000 | 5,194,000 | 344,000 | -2,311,000 | 5,876,000 | -2,321,000 | 9,000 | 2,225,000 | -284,000 | 3,296,000 | 499,000 | 448,000 | -1,550,000 |
| accrued compensation | 1,313,000 | -6,561,000 | 2,703,000 | 3,952,000 | 3,414,000 | -5,417,000 | 3,620,000 | 3,315,000 | 2,542,000 | -6,039,000 | 3,162,000 | 3,379,000 | 2,320,000 | -1,889,000 | 1,599,000 |
| accrued interest expense | 27,000 | 25,000 | 34,000 | 34,000 | 34,000 | 32,000 | 32,000 | 32,000 | 33,000 | 28,000 | 69,000 | 185,000 | 253,000 | 250,000 | 241,000 |
| loan facility liability | |||||||||||||||
| deferred revenue | -12,000 | 235,000 | 1,421,000 | 1,437,000 | 653,000 | 205,000 | 649,000 | 449,000 | 1,131,000 | 1,088,000 | 512,000 | 480,000 | 495,000 | 343,000 | 177,000 |
| reimbursements for leasehold improvements from operating leases | 0 | 0 | 2,596,000 | 0 | 1,772,000 | 3,217,000 | |||||||||
| other liabilities | 1,171,000 | 390,000 | 193,000 | 147,000 | 125,000 | 1,306,000 | -1,468,000 | -1,104,000 | 1,077,000 | 346,000 | 1,338,000 | 1,667,000 | 267,000 | -613,000 | 1,772,000 |
| net cash from operating activities | -15,043,000 | -16,980,000 | -32,391,000 | -18,800,000 | -15,736,000 | -32,286,000 | -24,793,000 | -18,943,000 | -28,339,000 | -35,928,000 | -25,174,000 | -19,851,000 | -17,126,000 | -18,231,000 | -16,476,000 |
| capex | -2,802,000 | -1,836,000 | -1,174,000 | -246,000 | -1,043,000 | -1,946,000 | -8,715,000 | -5,780,000 | -5,372,000 | -5,339,000 | -866,000 | -1,514,000 | -218,000 | -55,000 | -332,000 |
| free cash flows | -17,845,000 | -18,816,000 | -33,565,000 | -19,046,000 | -16,779,000 | -34,232,000 | -33,508,000 | -24,723,000 | -33,711,000 | -41,267,000 | -26,040,000 | -21,365,000 | -17,344,000 | -18,286,000 | -16,808,000 |
| cash flows from investing activities: | |||||||||||||||
| purchases of property and equipment | -2,802,000 | -1,836,000 | -1,174,000 | -246,000 | -1,043,000 | -1,946,000 | -8,715,000 | -5,780,000 | -5,372,000 | -5,339,000 | -866,000 | -1,514,000 | -218,000 | -55,000 | -332,000 |
| net cash from investing activities | -2,802,000 | -1,836,000 | -1,174,000 | -246,000 | -1,043,000 | -1,946,000 | -8,715,000 | -5,780,000 | -5,372,000 | -5,339,000 | -866,000 | -1,514,000 | -218,000 | -55,000 | -332,000 |
| cash flows from financing activities: | |||||||||||||||
| proceeds from issuance of common stock from the exercise of stock options | 873,000 | 1,298,000 | 3,601,000 | 1,715,000 | 3,173,000 | 2,586,000 | 973,000 | 414,000 | 713,000 | 380,000 | 367,000 | 777,000 | 1,573,000 | 1,291,000 | 689,000 |
| proceeds from issuance of common stock under employee stock purchase plan | 2,404,000 | 0 | 1,893,000 | 0 | 1,120,000 | 0 | |||||||||
| net cash from financing activities | 4,378,000 | 1,298,000 | 170,528,000 | 1,715,000 | 5,296,000 | 2,586,000 | 2,866,000 | 162,119,000 | 2,430,000 | 380,000 | -1,318,000 | 777,000 | 2,862,000 | 1,291,000 | 644,000 |
| effect of exchange rates on cash, cash equivalents and restricted cash | |||||||||||||||
| net decrease in cash, cash equivalents and restricted cash | -13,490,000 | -17,518,000 | -11,483,000 | -31,646,000 | -31,281,000 | -40,887,000 | -16,995,000 | ||||||||
| cash, cash equivalents and restricted cash | |||||||||||||||
| beginning of the period | 0 | 336,763,000 | 0 | 0 | 0 | 260,260,000 | 0 | 0 | 0 | 225,674,000 | 1,000 | -1,000 | 0 | 305,097,000 | 0 |
| end of the period | -13,490,000 | 319,245,000 | 136,963,000 | -17,331,000 | -11,483,000 | 228,614,000 | -30,642,000 | 137,396,000 | -31,281,000 | 184,787,000 | -27,357,000 | -20,589,000 | -14,482,000 | 288,102,000 | -16,164,000 |
| reconciliation of cash, cash equivalents and restricted cash to balance sheets: | |||||||||||||||
| cash and cash equivalents | -13,490,000 | 316,207,000 | 136,963,000 | -17,331,000 | -11,483,000 | 225,576,000 | -29,865,000 | 137,396,000 | -31,281,000 | 180,972,000 | -27,358,000 | -20,589,000 | -14,482,000 | 284,288,000 | -16,164,000 |
| restricted cash | 0 | 3,038,000 | 0 | 0 | 0 | 3,038,000 | -777,000 | 0 | 0 | 3,815,000 | 1,000 | 0 | 0 | 3,814,000 | 0 |
| cash, cash equivalents and restricted cash in balance sheets | -13,490,000 | 319,245,000 | 136,963,000 | -17,331,000 | -11,483,000 | 228,614,000 | -30,642,000 | 137,396,000 | -31,281,000 | 184,787,000 | -27,357,000 | -20,589,000 | -14,482,000 | 288,102,000 | -16,164,000 |
| supplemental cash flow information | |||||||||||||||
| interest paid | 869,000 | 885,000 | 924,000 | 1,011,000 | 1,031,000 | 1,004,000 | 1,004,000 | 988,000 | 943,000 | 1,121,000 | 718,000 | 1,204,000 | 1,198,000 | 1,171,000 | 1,184,000 |
| non-cash investing and financing activities | |||||||||||||||
| property and equipment included in accounts payable and accrued expenses | -775,000 | 1,388,000 | 323,000 | -56,000 | -478,000 | 559,000 | 2,269,000 | 351,000 | 10,000 | ||||||
| transfer of evaluation or rental units from inventory to property and equipment | 0 | -164,000 | 177,000 | ||||||||||||
| change in fair value in derivative liability | 27,000 | ||||||||||||||
| loss on loan extinguishment | |||||||||||||||
| operating lease liabilities | |||||||||||||||
| proceeds from issuance of common stock, net of issuance costs | |||||||||||||||
| proceeds from issuance of long-term debt, net of issuance costs | |||||||||||||||
| payment of principal on long-term debt | |||||||||||||||
| payment of final payment fee | |||||||||||||||
| payment of prepayment fee | |||||||||||||||
| net increase in cash, cash equivalents and restricted cash | 136,963,000 | -30,642,000 | -27,358,000 | -20,588,000 | -16,164,000 | ||||||||||
| transfer of evaluation units from inventory to property and equipment | 470,000 | 0 | -61,000 | -62,000 | -79,000 | 150,000 | 548,000 | ||||||||
| right-of-use assets obtained in exchange for operating lease liabilities | |||||||||||||||
| proceeds from the issuance of common stock, net of issuance costs | |||||||||||||||
| change in fair value in derivative liability and redeemable convertible preferred stock warrants | |||||||||||||||
| proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses | -45,000 | ||||||||||||||
| proceeds from the exercise of redeemable convertible preferred stock warrants | 0 | ||||||||||||||
| proceeds from issuance of series g redeemable convertible preferred stock, net of issuance costs | 0 | ||||||||||||||
| property and equipment included in accounts payable and other current liabilities | 5,881,000 | -366,000 | |||||||||||||
| right-of-use-assets obtained in exchange for operating lease liabilities | |||||||||||||||
| change in fair value of redeemable convertible preferred stock warrants and derivative liability | 170,000 | 39,000 | 37,000 | 37,000 | 36,000 | ||||||||||
| proceeds from issuance of series g preferred stock, net of issuance costs | |||||||||||||||
| deferred offering costs included in accounts payable and other current liabilities | |||||||||||||||
| other non-cash expense | |||||||||||||||
| proceeds from issuance of note payable, net of issuance costs | |||||||||||||||
| proceeds from issuance of series f redeemable convertible preferred stock, net of issuance costs | |||||||||||||||
| conversion of redeemable convertible preferred stock to common stock | |||||||||||||||
| non-cash lease expense |
We provide you with 20 years of cash flow statements for PROCEPT BioRobotics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PROCEPT BioRobotics stock. Explore the full financial landscape of PROCEPT BioRobotics stock with our expertly curated income statements.
The information provided in this report about PROCEPT BioRobotics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.